Stem cell agency hunts for new leader – Capitol Weekly
Capitol Weekly |
Stem cell agency hunts for new leader
Capitol Weekly California’s $3 billion stem cell research program is looking for a new president to carry the state agency through what may be the last three years of its life. The search committee of the agency’s 29-member governing board meets July 17 to discuss … |
Rare Disease Report |
FDA Advisory Board and Novartis to Discuss Leukemia Gene Therapy Wednesday
Rare Disease Report On Wednesday, the Oncology Drug Advisory Committee for the U.S. Food and Drug Administration (FDA) will review Novartis AG’s experimental gene therapy drug tisagenlecleucel, with a specific focus on the safety of the potential leukemia treatment. Before Key Meeting, FDA Stresses Risks of Novartis CAR-T Cancer TherapyXconomy BRIEF-Inficon expects H1 sales of around $182 millionReuters UK |
Madison.com |
UW-Madison scientists grow functional artery cells from stem cells
Madison.com Jue Zhang, a scientist in James Thomson’s lab at the Morgridge Institute for Research at UW-Madison, carries a stem cell culture tray used in research on growing arteries. Zhang, Thomson and others in the lab have grown artery cells from stem cells … Stem cell advance brings bioengineered arteries closer to realityEurekAlert (press release) |
|
Stem cell-based therapy for targeting skin-to-brain cancer
EurekAlert (press release) Investigators from Brigham and Women’s Hospital (BWH) and the Harvard Stem Cell Institute have a potential solution for how to kill tumor cells that have metastasized to the brain. The team has developed cancer-killing viruses that can deliver stem … |
|
New tool for the synthetic biologist’s toolbox invented: Researchers …
Science Daily A new method for controlling gene expression across bacterial colonies has been invented by researchers. The method involves engineering dynamic DNA … |
Xconomy |
Before Key Meeting, FDA Stresses Risks of Novartis CAR–T Cancer Therapy
Xconomy If approved for kids and young adults with acute lymphoblastic leukemia, or ALL, it would likely be the first so-called CAR-T medicine to reach the market. The field has faced years of intense scrutiny and questions about whether a patient’s own T … Safety issues for Novartis CAR–T therapy main focus of FDABioPharma Dive |
Madison.com |
CRISPR Therapeutics, Neon Therapeutics Enter Research Collaboration
GenomeWeb NEW YORK (GenomeWeb) – CRISPR Therapeutics and Neon Therapeutics said today that they have entered a research collaboration to explore using a combination of each company’s proprietary technologies to develop novel T cell therapies. Why CRISPR Therapeutics AG Jumped 11.7% in JuneMadison.com CRISPR Therapeutics and Neon Therapeutics Enter Research CollaborationGlobeNewswire (press release) CRISPR Therapeutics teams up with Neon Therapeutics to develop T cell therapiesInvesting.com The Cerbat Gem –Community Financial News –Sports Perspectives all 9 news articles » |